RxDoctor Payments Data

Michelle Mourre

Gerontology · Boerne, TXNPI 1295331858

Payments from drug & device makers

$2,858in general payments, 2019–2025

Across 132 payments — averaging $21.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$596
  • Neurocrine Biosciences, Inc.$578
  • Lilly USA, LLC$291
  • AstraZeneca$288
  • Exact Sciences$171
  • Johnson & Johnson$170
  • plus $763 from 18 others

What the payments were for

  • Food & beverage$2,858100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,858 in reported general payments places this provider in the 85th percentile of 653 gerontology providers in Texas.

See all gerontology providers in Texas

Medicare billing

Part B allowed, 2024
$97,505
Medicare patients
187
Services billed
1,068

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide90$95,117
JardianceEmpagliflozin45$46,052
FarxigaDapagliflozin Propanediol27$31,015
OzempicSemaglutide28$25,982
EliquisApixaban40$25,040
MyrbetriqMirabegron16$15,226
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,765
QuviviqDaridorexant Hcl11$5,456
ValacyclovirValacyclovir Hcl17$2,017
SynthroidLevothyroxine Sodium20$1,957
Levothyroxine Sodium162$1,626
ProgesteroneProgesterone, Micronized32$1,137
Estradiol21$1,043
Atorvastatin Calcium124$1,021
Omeprazole64$982

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$291$95,11790 claims
AstraZenecaFarxiga$288$31,01527 claims
Novo NordiskOzempic$64$25,98228 claims
PfizerEliquis$13$25,04040 claims
Astellas Pharma US IncMyrbetriq$54$15,22616 claims
Idorsia Pharmaceuticals US IncQuviviq$95$5,45611 claims
AbbVieSynthroid$15$1,95720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 653 gerontology providers in Texas.

Other gerontology in Boerne

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →